Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Harness lncRNA targeting to treat colorectal cancer

Project description

An RNA target in colorectal cancer

To safeguard cell division, cells have evolved mechanisms such as the replication stress response that stabilises replication stalling and repairs DNA damage. Because cancer cells divide rapidly, they depend heavily on this pathway, making it a common target in therapy. However, inhibiting the replication stress response directly can disrupt essential processes, causing toxicity and limiting clinical benefit. The ERC-funded LINCURE project takes a more selective approach by targeting long non-coding RNAs (lncRNAs) known for their role in gene expression regulation. The work will investigate a previously identified lncRNA implicated in the replication stress response. Researchers will inhibit this lncRNA in colorectal cancer cells with the aim to advance RNA-based delivery systems and find new therapies.

Objective

Colorectal cancer (CRC) is the third leading cause of cancer-related death globally. Despite the therapeutic advances, innate and acquired resistance is still an adversity that needs to be overcome. Therefore, there is an urgent need to identify more targeted and specific therapeutic approaches in order to increase success of the treatment and reduce the medical and economic burden of therapeutic failures. Numerous studies have been conducted to target the replication stress response, a hallmark of cancer and drug resistance, in cancer therapy. However, hitting this essential pathway can trigger deleterious and non-specific cellular responses.
Our research introduces a novel perspective to this problem by focusing on the RNA components of the replication stress pathway. lncRNAs are untranslated RNAs whose emerging role in regulating gene expression has changed the way we look at genes and their functions. lncRNAs play a regulatory role in mechanisms of acquired tumour drug resistance. Moreover, their rapid turnover, tissue and pathology specificity make them ideal targets for effective therapeutic avenues that don’t bare the same toxicity as conventional approaches.
Our dedicated ERC research has unveiled a lncRNA with remarkable biological properties. CRC cells subjected to replicative stress are addicted to its expression, representing a highly promising therapeutic target. Building on these novel findings, we propose LINCURE, a new therapy based on the inhibition of this lncRNA. lncRNA inhibitors will be used alone or in combination with the conventional 5-FU therapy to reach therapeutic efficacy for drug resistant CRC. We will integrate our unique knowledge with recent advancements in the successful development of delivery methods for RNA-based therapies, which have generated a surge of optimism in the realm of RNA therapeutics. The objective is to start a promising pathway toward translating our findings into effective clinical therapies.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Net EU contribution
€ 110 000,00
Address
AVENIDA DE PIO XII 55
31008 Pamplona
Spain
Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)